FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075667178> ?p ?o ?g. }

• W2075667178 endingPage "239" @default.
• W2075667178 startingPage "232" @default.
• W2075667178 abstract "This phase 1 clinical trial was conducted to evaluate the safety and to determine the maximum tolerated dose (MTD) of the immunocytokine EMD 273066 huKS-IL2 and, secondarily, to assess its pharmacokinetics, immunogenic potential, and immunologic activity in patients with androgen-independent prostate cancer (n = 22). EMD 273066 was administered in 3-day cycles (separated by 4 weeks) of once-daily, 4-hour intravenous infusions at a dose determined by an escalation protocol (0.4, 0.7, 1.4, 2.8, 4.3, 6.4, or 8.5 mg/m/d). Approximately 2/3 of patients received a second cycle of treatment. The results show that the MTD of EMD 273066 [ie, one dose level below that producing dose-limiting toxicity (DLT) in at least 33% of patients in a dosing group] was 6.4 mg/m/d. EMD 273066 was generally well tolerated up to a dose of 4.3 mg/m/d. No DLTs, defined as drug-related toxicities >OR= Grade 3 occurring during the first treatment cycle, were observed among patients in the 0.4-, 0.7-, 1.4-, or 4.3-mg/m/d dosing groups. Four patients treated with 2.8, 6.4, or 8.5 mg/m/d EMD 273066 experienced DLTs. Titers of both antiimmunocytokine and anti-FcIL-2 antibody responses were observed after the first dose cycle and either decreased or remained stable during a second course of treatment. No hypersensitivity reactions were observed. EMD 273066 exhibited immunologic activity as demonstrated by increases in lymphocyte counts, natural killer cell number and specific activity, and antibody-dependent cellular cytotoxicity activity. On average, Cmax, which was dose-dependent, was achieved within 1 hour after infusion. Mean t(1/2) which was independent of dose, ranged from 4.0 to 6.7 hours across doses. A zero-compartment body model with one-order kinetics best described the concentration-time profiles. These data demonstrate that the novel immunocytokine EMD 273066 is well tolerated at doses above a level of observed systemic biologic activity in patients with androgen-independent prostate cancer." @default.
• W2075667178 created "2016-06-24" @default.
• W2075667178 creator A5000263428 @default.
• W2075667178 creator A5005350858 @default.
• W2075667178 creator A5013741866 @default.
• W2075667178 creator A5043769628 @default.
• W2075667178 creator A5043919496 @default.
• W2075667178 creator A5073111231 @default.
• W2075667178 creator A5073454853 @default.
• W2075667178 creator A5087064759 @default.
• W2075667178 creator A5089524539 @default.
• W2075667178 date "2004-01-01" @default.
• W2075667178 modified "2023-10-16" @default.
• W2075667178 title "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)" @default.
• W2075667178 cites W1950572133 @default.
• W2075667178 cites W1966204823 @default.
• W2075667178 cites W1973724116 @default.
• W2075667178 cites W1975568557 @default.
• W2075667178 cites W1981743199 @default.
• W2075667178 cites W2005112283 @default.
• W2075667178 cites W2018323373 @default.
• W2075667178 cites W2022565486 @default.
• W2075667178 cites W2049020751 @default.
• W2075667178 cites W2065830732 @default.
• W2075667178 cites W2090242584 @default.
• W2075667178 cites W2123914905 @default.
• W2075667178 cites W2124446900 @default.
• W2075667178 cites W2141086589 @default.
• W2075667178 cites W2169355589 @default.
• W2075667178 cites W2186456488 @default.
• W2075667178 cites W2277257507 @default.
• W2075667178 cites W2330612110 @default.
• W2075667178 doi "https://doi.org/10.1097/00002371-200405000-00008" @default.
• W2075667178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15076141" @default.
• W2075667178 hasPublicationYear "2004" @default.
• W2075667178 type Work @default.
• W2075667178 sameAs 2075667178 @default.
• W2075667178 citedByCount "58" @default.
• W2075667178 countsByYear W20756671782012 @default.
• W2075667178 countsByYear W20756671782013 @default.
• W2075667178 countsByYear W20756671782014 @default.
• W2075667178 countsByYear W20756671782015 @default.
• W2075667178 countsByYear W20756671782016 @default.
• W2075667178 countsByYear W20756671782017 @default.
• W2075667178 countsByYear W20756671782019 @default.
• W2075667178 countsByYear W20756671782020 @default.
• W2075667178 countsByYear W20756671782021 @default.
• W2075667178 countsByYear W20756671782022 @default.
• W2075667178 crossrefType "journal-article" @default.
• W2075667178 hasAuthorship W2075667178A5000263428 @default.
• W2075667178 hasAuthorship W2075667178A5005350858 @default.
• W2075667178 hasAuthorship W2075667178A5013741866 @default.
• W2075667178 hasAuthorship W2075667178A5043769628 @default.
• W2075667178 hasAuthorship W2075667178A5043919496 @default.
• W2075667178 hasAuthorship W2075667178A5073111231 @default.
• W2075667178 hasAuthorship W2075667178A5073454853 @default.
• W2075667178 hasAuthorship W2075667178A5087064759 @default.
• W2075667178 hasAuthorship W2075667178A5089524539 @default.
• W2075667178 hasConcept C111113717 @default.
• W2075667178 hasConcept C112705442 @default.
• W2075667178 hasConcept C121608353 @default.
• W2075667178 hasConcept C126322002 @default.
• W2075667178 hasConcept C2777288759 @default.
• W2075667178 hasConcept C2780192828 @default.
• W2075667178 hasConcept C29730261 @default.
• W2075667178 hasConcept C71924100 @default.
• W2075667178 hasConcept C90924648 @default.
• W2075667178 hasConcept C98274493 @default.
• W2075667178 hasConceptScore W2075667178C111113717 @default.
• W2075667178 hasConceptScore W2075667178C112705442 @default.
• W2075667178 hasConceptScore W2075667178C121608353 @default.
• W2075667178 hasConceptScore W2075667178C126322002 @default.
• W2075667178 hasConceptScore W2075667178C2777288759 @default.
• W2075667178 hasConceptScore W2075667178C2780192828 @default.
• W2075667178 hasConceptScore W2075667178C29730261 @default.
• W2075667178 hasConceptScore W2075667178C71924100 @default.
• W2075667178 hasConceptScore W2075667178C90924648 @default.
• W2075667178 hasConceptScore W2075667178C98274493 @default.
• W2075667178 hasIssue "3" @default.
• W2075667178 hasLocation W20756671781 @default.
• W2075667178 hasLocation W20756671782 @default.
• W2075667178 hasOpenAccess W2075667178 @default.
• W2075667178 hasPrimaryLocation W20756671781 @default.
• W2075667178 hasRelatedWork W2004325424 @default.
• W2075667178 hasRelatedWork W2021319218 @default.
• W2075667178 hasRelatedWork W2227061539 @default.
• W2075667178 hasRelatedWork W2245370565 @default.
• W2075667178 hasRelatedWork W2400384365 @default.
• W2075667178 hasRelatedWork W2403251648 @default.
• W2075667178 hasRelatedWork W2594910449 @default.
• W2075667178 hasRelatedWork W2992709639 @default.
• W2075667178 hasRelatedWork W3021369409 @default.
• W2075667178 hasRelatedWork W3174177415 @default.
• W2075667178 hasVolume "27" @default.
• W2075667178 isParatext "false" @default.
• W2075667178 isRetracted "false" @default.
• W2075667178 magId "2075667178" @default.
• W2075667178 workType "article" @default.